--- vault_clearance: EUCLID halo: classification: INTERNAL custodian: The Architect created: 2026-04-26 confidence: HIGH front: "Operational map of the cellular encoding architecture" updated: 2026-04-26 wing: UNASSESSED --- # FORM — 35_Project_TheHats — operational map of the cellular encoding architecture ## Purpose This file is the **architectural blueprint** of what we're measuring. It lays out the encoding layers, what each layer does, what observable property each lays down, what we measure to read it, and what tools / data we need. Every "hat" the cell wears corresponds to a layer here. Reading the cell's full source code = profiling all layers simultaneously. ## The architecture (10 measurable layers) ``` ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 0: DNA — archival, cell-identity-stable │ │ Read by: cell itself │ │ Adversary cannot read: physically inside nucleus │ │ Measurable: WGS / WES (we don't measure this — focus is RNA→prot) │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 1: Pre-mRNA — full transcript with introns + alt-TSS │ │ Information: which gene is being transcribed, alt-TSS choice │ │ Crypto role: Stage 1 routing — what enters the splicing pipeline │ │ Privacy: pre-mRNA is intracellular and transient │ │ Adversary access: NONE (transient nuclear) │ │ Measurement: nascent-RNA-seq (NET-seq, GRO-seq) │ │ Status: NOT MEASURED in cohort │ └────────────────────────────────────────────────────────────────────┘ │ splicing decisions │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 2: Mature mRNA — alt splicing, intron retention │ │ Information: which isoform makes it through │ │ Crypto role: protocol-pivot capacity (HALO_ENCODING §7) │ │ Privacy: short-lived, intracellular, but somewhat readable │ │ Adversary access: only via single-cell lysis │ │ Measurement: scRNA-seq, BAM CIGAR-N junction analysis │ │ Status: ★ MEASURED VIA atlas_full6.db + STAFF C-kernel pipeline │ │ BT83-BT88 results live here │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 3: RNA modifications (m6A, Ψ, m5C) │ │ Information: self-marker watermark per transcript │ │ Crypto role: authentication watermark (HALO_ENCODING §6) │ │ Privacy: visible to RIG-I/MDA5; foreign RNA lacks it │ │ Adversary access: viruses must evolve to add modifications │ │ Measurement: MeRIP-seq, m6A-MAP, Ψ-seq │ │ Status: NOT MEASURED in cohort, public data exists in GEO │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 4: Codon usage / translation kinetics │ │ Information: per-tissue private channel via tRNA-pool match │ │ Crypto role: per-tissue cipher key (HALO_ENCODING §2) │ │ Privacy: visible only to systems running through the host │ │ translational machinery │ │ Adversary access: pathogens MUST match host codon bias to spoof │ │ Measurement: per-gene codon frequency vs. cell-type tRNA pool │ │ (CAI = Codon Adaptation Index, tAI = tRNA AI) │ │ Status: NOT MEASURED, COMPUTABLE from existing BAM + reference │ └────────────────────────────────────────────────────────────────────┘ │ translation │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 5: Protein primary sequence — wobble-projected from mRNA │ │ Information: AA chain │ │ Crypto role: lossy hash output — RNA inventory irrecoverable │ │ Privacy: same protein from different codons indistinguishable │ │ Adversary access: visible to ribosome / proteasome / MHC-I │ │ Measurement: implicit in protein presence; no special tool │ │ Status: standard │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 6: IDR (intrinsically disordered regions) content │ │ Information: structural-unverifiability mass per protein │ │ Crypto role: unforgeable polymorphism (HALO_ENCODING §3) │ │ Privacy: pathogens cannot mimic by structural matching │ │ Adversary access: limited — IDRs DON'T present clean structure │ │ Measurement: IUPred3, MobiDB, ESM2 disorder predictor │ │ Status: NOT MEASURED, COMPUTABLE from sequence (no BAM needed) │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 7: Low-complexity regions / repeat regions │ │ Information: high-mutation-rate per-individual identity tags │ │ Crypto role: per-individual fingerprinting (HALO_ENCODING §4) │ │ Privacy: per-individual variation prevents population mimicry │ │ Adversary access: pathogens trained on population see consensus │ │ not the individual variant │ │ Measurement: SEG, BLAST low-complexity filter │ │ Status: NOT MEASURED, COMPUTABLE from sequence │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 8: Folded protein — chaperone-verified 3D structure │ │ Information: fold family, structural identity │ │ Crypto role: structural authentication (3D verification) │ │ Privacy: misfolded → ERAD / UPR / proteasome destruction │ │ Adversary access: pathogens must reproduce fold to spoof │ │ Measurement: implicit; AlphaFold predictions per protein │ │ Status: predictable; aggregating per cell type adds power │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 9: Post-translational modifications (phospho, acetyl, etc.) │ │ Information: state-dependent runtime tags │ │ Crypto role: programmable switches (HALO_ENCODING §11) │ │ Privacy: PTMs require host-specific enzymes │ │ Adversary access: pathogens must hijack host PTM machinery │ │ Measurement: phospho-proteomics, acetyl-proteomics │ │ Status: NOT MEASURED, public data exists │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 10: Glycosylation — second crypto layer │ │ Information: 200+ sugars / linkages = high-diversity code │ │ Crypto role: SECOND crypto layer (HALO_ENCODING §5) │ │ Privacy: per-individual (ABO/Lewis blood types), per-tissue │ │ Adversary access: requires full host glycosyltransferase repertoire │ │ Measurement: NetNGlyc + NetOGlyc (sites); glycomics (composition) │ │ Status: NOT MEASURED, COMPUTABLE for sites; composition needs proteomics │ └────────────────────────────────────────────────────────────────────┘ │ ▼ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 11 (broadcast surface): MHC-I peptide presentation │ │ Information: subset of the proteome surfaced for T-cell scan │ │ Crypto role: BROADCAST — what the cell deliberately reveals │ │ Privacy: cell selects which proteasome products reach surface │ │ Adversary access: visible to T cells (the intended audience) │ │ Measurement: immunopeptidomics (MS-based) │ │ Status: NOT MEASURED in our cohort │ └────────────────────────────────────────────────────────────────────┘ ┌────────────────────────────────────────────────────────────────────┐ │ LAYER 12 (paracrine): exosomes / EVs — encrypted RNA + protein │ │ Information: cargo (mRNA + miRNA + lncRNA + protein), addressing │ │ Crypto role: encrypted packets with surface addressing markers │ │ Privacy: lipid envelope blocks RNase; receptor-matched uptake │ │ Adversary access: limited to receivers with matching receptors │ │ Measurement: exosome RNA-seq + tetraspanin profiling │ │ Status: NOT MEASURED in our cohort │ └────────────────────────────────────────────────────────────────────┘ ``` ## Measurement priorities The layers we can measure CHEAPLY (sequence-based or atlas-based, no new wet-lab data): - ★ **Layer 2 (alt splicing / IR)** — already done, atlas + BT86 - **Layer 4 (codon usage)** — sequence-based, computable from BAM + reference (1-2 days) - **Layer 6 (IDR content)** — sequence-based via IUPred3 (1 day) - **Layer 7 (low-complexity content)** — sequence-based via SEG (hours) - **Layer 10a (glyco SITES)** — sequence-based via NetNGlyc / NetOGlyc (1-2 days) - **Layer 8 (fold family)** — predictable via AlphaFold structures (existing public DB) The layers requiring **new public-data acquisition**: - **Layer 3 (m6A)** — public MeRIP-seq from GEO, must integrate - **Layer 9 (PTMs)** — public phospho-proteomics, must integrate - **Layer 10b (glyco COMPOSITION)** — glycomics, sparser data - **Layer 11 (immunopeptidome)** — public MHC-I data exists for some cell types - **Layer 12 (exosome cargo)** — public datasets exist The layers we **cannot easily measure**: - **Layer 1 (nascent RNA)** — would require NET-seq / GRO-seq generation - **Layer 5/8 (folded protein presence per cell)** — proteomics needed ## The privacy-stack-depth metric Per cell type, a single integrated score: ``` PRIVACY_STACK_DEPTH(cell_type) = f( splicing_variance, # Layer 2 — from BT86 framework codon_bias_strength, # Layer 4 — Tier-0 task idr_load, # Layer 6 — Tier-0 task low_complexity_load, # Layer 7 — Tier-0 task glyco_site_density # Layer 10a — Tier-0 task ) ``` Where `f` is some integration function (geometric mean, weighted sum, or entropy-based). The choice of `f` is itself a Tier-1 task to test against predictive power on TCGA. ## Predicted patterns Based on `HALO_ENCODING_AS_CS_PROBLEM`: | cell type | predicted privacy-stack depth | |---|---| | **Healthy primary differentiated cells** | DEEP (full stack engaged) | | **Stem cells / progenitors** | DEEP (need to remain hidden during expansion) | | **Senescent cells (BT86 / our cohort)** | DEEP at splicing layer (BT86 confirmed); other layers unknown | | **Cancer cells (proliferating tumor)** | SHALLOW at multiple layers (the testable prediction) | | **Immune-privileged-site cells (eye, brain, testis)** | SHALLOWER (less need for privacy in privileged niches) | | **Activated immune cells (signaling broadly)** | INTERMEDIATE — broadcasting more, hiding less, but still verified | | **Embryonic / fetal cells** | DEEP (high privacy investment for development protection) | | **Senescent + cancer-passaged (e.g. SCC)** | UNCERTAIN — competing pressures | These are testable predictions. Each provides a ground-truth case for validating the metric. ## First-pass empirical results — splicing layer (Day 1, 10-sample gradient) The first measurement run on Layer 2 (splicing) showed two distinct "broken tool" patterns at the SF expression + variety + concentration levels: ### Per-million-reads junction diversity | group | sample | unique junctions per M reads | top 50% in % of junctions | |---|---|---:|---:| | fetal | H9_fetal (ESC) | **271,000** | 3.0% (FLATTEST) | | cancer (bulk) | HepG2_HCC | 94,000 | 1.06% | | cancer (bulk) | K562_CML | 126,000 | 1.33% | | cancer (10x sc) | Zilionis_NSCLC | 4,634 | **0.22% (MOST CONCENTRATED)** | | prol (10x sc) | cohort P1-P3 | 3,200-3,300 | ~0.18% | | sen (10x sc) | cohort S1-S3 | 3,100-3,500 | ~0.20% | **Bulk-only comparison (apples-to-apples): fetal is 2-3× more diverse per read than cancer.** ### SF expression two-pattern signature - **Senescent (cohort):** uniform -17% across all 7 SFs, range 0.74-0.95 → **range 0.20 (LOW variance, COORDINATED)** - **Cancer (bulk vs fetal):** variable -15% to -70% across SFs → **range 0.49-0.52 (HIGH variance, DYSREGULATED)** **Senescent looks coordinated. Cancer looks chaotic.** Both reduce SF expression overall, but via different mechanisms. ### Two distinct "broken tool" regimes | | fetal | proliferative | senescent | cancer | |---|---|---|---|---| | SF expression | HIGHEST | HIGH | -17% (uniform) | variable -15-70% | | Junction variety | HIGHEST | HIGH | preserved (~99%) | LOWER (35-46% of fetal) | | Concentration | flattest (3.0%) | similar to sen | similar to prol | most concentrated (0.22-1.3%) | | Pattern | full precision | full precision | **engineered uniform regression** | **emergent dysregulation** | This empirically grounds `HALO_DELIBERATELY_BROKEN.md`'s framework distinction: - Senescent is doing **deliberate privacy regression** (uniform downsizing, preserved variety, targeted gene-level redirection per BT86 hot zones). - Cancer is doing **dysregulated parser collapse** (chaotic SF reduction, variety collapse, concentrated parser usage). May be compromised regulation OR a different privacy strategy operating on other layers (MHC-I downregulation, CD47, PD-L1). The **operator's "fetal → proliferative → senescent/cancer = decreasing splicing variety" intuition is empirically confirmed**, with the refinement that senescent and cancer arrive at "less variety" via different mechanisms. ## Connection to the cohort empirics The HAEC+PBMC cohort (BT85/86) operationalizes this for the splicing layer: - 6 samples, 374-382M reads each - 1.2M+ junctions identified per sample via STAFF C-kernel - 15,658 junctions show ≥2× P-vs-S splice-rate change - Coordinated hot zones at chr14:55M, chr17:40M (proliferation), chr20:31.7M (TPX2), chr4:103M (CENPE), chr7:36-119M (RALA-containing), chr2:110-124M (RALB-containing) - Senescent cells hide BOTH proliferation machinery AND trafficking-rewiring genes (BT88) Adding Layer 4 (codon usage), Layer 6 (IDR), Layer 7 (low-complexity), Layer 10a (glyco sites) will give a 5-layer profile per sample. Then we can compute the privacy-stack-depth per sample-state and validate cancer/senescence predictions. ## Next steps 1. **Tier 0 measurement infrastructure** (4 tasks in BOUNTY_BOARD) 2. **Tier 1 integration** (privacy-stack-depth metric definition + cohort validation) 3. **Tier 2 cancer prediction** (TCGA tumor-vs-normal validation) The architecture is the map. The bounty board is the route. WORLDLINE is the log of how we got here. README is the why.